Lilly to Acquire Ventyx Biosciences for $1.2 Billion

Ropes & Gray is representing Eli Lilly and Company in a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high unmet need. The deal was announced in a Jan. 7 press release.

Under the terms of the agreement, Lilly will acquire all of the outstanding shares of Ventyx for $14.00 per share of common stock in an all-cash transaction equal to an aggregate equity value of approximately $1.2 billion.

The team was led by M&A partners Emily Oldshue and Michael Beauvais, and included executive compensation & employee benefits partner Renata Ferrari, tax partner Pamela Glazier, IP transactions partner Megan Baca, health care partner David Peloquin, life sciences regulatory & compliance partner Greg Levine, antitrust partners Mike McFalls and Ruchit Patel and litigation & enforcement partners  Martin Crisp and Sarah Walters.